Table 1.

Current systemic therapies available for melanoma.

Chemotherapy	Targeted Therapy	Immunotherapy	Combinational
Dacarbazine Temozolamide Carboplatin/cisplatin Vincristine/vinblastine Carmustine/fotemustine	BRAF inhibitors (Vemurafenib) (Dabrafenib) (Encorafenib) MEK inhibitors (Trametinib) (Cobimetinib) (Binimetinib)	CTLA-4 mAb (Ipilimumab) PD-1 mAb (Nivolumab) (Pembrolizumab) Recombinant IFNα2b Recombinant IL-2 T-VEC	Dabrafenib + trametinib Vemurafenib + cobimetinib Encorafenib + binimetinib Nivolumab + ipilimumab

mAb: monoclonal antibody; CTLA-4: T-lymphocyte-associated protein-4; PD-1: programmed cell death protein-1; IFN-α: interferon alpha; IL-2: interleukin-2; T-VEC: Talimogene laherparepvec; BRAF: serine/threonine protein kinase B-raf; MEK: mitogen activated protein kinase.